Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services

被引:4
|
作者
Walker, Andrew [1 ]
机构
[1] Calderdale & Huddersfield NHS Fdn Trust, Dept Pharm, Huddersfield, W Yorkshire, England
关键词
Neurotrophic tyrosine receptor kinase; larotrectinib; entrectinib; neurotrophic tyrosine receptor kinase inhibitor; oncology; ETV6-NTRK3 GENE FUSION; CANCER; TROPOMYOSIN; THERAPIES; PATHOLOGY; ONCOGENE; TRK;
D O I
10.1177/1078155220959428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neurotrophic tyrosine receptor kinase (NTRK) inhibitors represent the latest advancement as a treatment option in targeted therapies for malignant disease. NTRK gene fusions involving NTRK1, 2 or 3 are implicated as genetics drivers for a number of tumour types which arise within adult and paedatric patients. NTRK inhibitors (Larotrectinib and Entrectinib) are effective agents which have demonstrated clinical benefit in the treatment of NTRK fusion positive solid tumours. Larotrectinib represents the first targeted agent to receive approval from international authorisation and commissioning bodies for the treatment of a specific genetic expression indiscriminate of the site from which the tumour has arisen. As such NTRK inhibitors could pave the way for international healthcare bodies to adopt a similar approach for future targeted therapies thereby altering the manner in which healthcare providers and patients are able to access and utilise innovative, targeted treatment options in future. The potential implications of this new approach are likely to impact upon several aspects of the traditional authorisation and commissioning pathways with potential changes to the design of clinical trials, the review and approval process by regulatory bodies and immunohistopathology services.
引用
收藏
页码:2015 / 2019
页数:5
相关论文
共 50 条
  • [21] Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Implications for Therapeutic Drug Monitoring
    Josephs, Debra H.
    Fisher, Danielle S.
    Spicer, James
    Flanagan, Robert J.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 562 - 587
  • [22] Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance
    Busse, D
    Yakes, FM
    Lenferink, AEG
    Arteaga, CL
    SEMINARS IN ONCOLOGY, 2001, 28 (05) : 47 - 55
  • [23] Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
    Hartmann, Joerg Thomas
    Haap, Michael
    Kopp, Hans-Georg
    Lipp, Hans-Peter
    CURRENT DRUG METABOLISM, 2009, 10 (05) : 470 - 481
  • [24] Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
    Pezzilli, Raffaele
    Fabbri, Dario
    Imbrogno, Andrea
    Corinaldesi, Roberto
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2011, 5 (02) : 165 - 168
  • [25] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Ozmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [26] Bcr-Abl tyrosine kinase inhibitors: a patent review
    Desogus, Andrea
    Schenone, Silvia
    Brullo, Chiara
    Tintori, Cristina
    Musumeci, Francesca
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (04) : 397 - 412
  • [27] Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review
    Yang, Jason J.
    Maloney, Nolan J.
    Nguyen, Kevin A.
    Worswick, Scott
    Smogorzewski, Jan
    Bach, Daniel Q.
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [28] A review on tyrosine kinase inhibitors for targeted breast cancer therapy
    Sankarapandian, Vidya
    Rajendran, Ramya Lakshmi
    Miruka, Conrad Ondieki
    Sivamani, Poornima
    Maran, Balu Alagar Venmathi
    Krishnamoorthy, Rajapandiyan
    Gangadaran, Prakash
    Ahn, Byeong-Cheol
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [29] Tyrosine kinase inhibitors in Ewing’s sarcoma: a systematic review
    Ahmad Assi
    Mohamad Farhat
    Rami Mohanna
    Maria Catherine Rita Hachem
    Ziad Zalaquett
    Marven Aoun
    Sami Abi Farraj
    Mohammad Daher
    Amer Sebaaly
    Hampig-Raphaël Kourie
    BMC Cancer, 25 (1)
  • [30] Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
    Pajares, Bella
    Torres, Esperanza
    Manuel Trigo, Jose
    Isabel Saez, Maria
    Ribelles, Nuria
    Jimenez, Begona
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02): : 94 - 101